References
- Freestone B, Lip GYH. Epidemiology and costs of cardiac arrhythmias. In: Cardiac Arryhythmias: a Clinical Approach. Lip GYH, Godtfredson J (Eds). Mosby, Edinburgh, UK, 3–24 (2003).
- Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D’Agostino RB. Secular trends in the prevalence of atrial fibrillation: the Framingham study. Am. Heart J.131, 790–795 (1996).
- Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population based cohort: the Framingham heart study. J. Am. Med. Assoc.271, 840–844 (1994).
- Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am. J. Cardiol.74, 236–241 (1994).
- Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation89, 224–227 (1994).
- Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation98, 946–952 (1998).
- Go AS, Hylek EM, Phillips KA. Prevalence of diagnosed atrial fibrillation in adults; national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA285, 2370–2375 (2001).
- Lip GYH, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelgatran in patients with atrial fibrillation: a systematic review and meta-analysis. Thromb. Res.118(3), 321–333 (2006).
- Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann. Int. Med.131, 492–501 (1999).
- Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke prevention in Atrial Fibrillation investigators. J. Am. Coll. Cardiol.35, 183–187 (2000).
- Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation, a major contributor to stroke in the elderly – the Framingham Study. Arch. Int. Med.147, 1561–1564 (1987).
- Choudhury A, Lip GYH. Atrial fibrillation and the hypercoaguable state: from basic science to clinical practice. Pathophysiol. Haemost. Thromb.33, 282–289 (2003).
- Wolf PA, Belanger AJ, Kannel WB, D’Agostino RB. Probabilty of stroke: a risk profile from Framingham study. Stroke22, 312–338 (1991).
- Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation: the Framingham study. Stroke27, 1760–1764 (1996).
- Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet1, 175–179 (1989).
- Steger C, Pratter A, Martinek-Bregel M et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur. Heart J.25, 1734–1740 (2004).
- European Atrial Fibrillation Study Group (EAFT). Secondary prevention in non rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet342, 1255–1262 (1993).
- Chugh SS, Joseph L, Blackshear, Shen WK, Stephen C, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J. Am. Coll. Cardiol.37, 371–378 (2001).
- Antani MR, Beyth RJ, Covinsky KE et al. Failure to prescribe warfarin to patients with non rheumatic atrial fibrillation. J. Gen. Int. Med.11, 713–720 (1996).
- Ezekowitz MD, James KE, Nazarian SM et al. Silent cerebral infarction in patients with non-rheumatic atrial fibrillation. The Veterans Affairs stroke prevention in non rheumatic atrial fibrillation investigators. Circulation92, 2178–2182 (1995).
- Van Walraven C, Hart RJ, Singer DE et al. anticoagulants vs aspirin in non rheumatic atrial fibrillation: an individual patient meta-analysis. JAMA288, 2441–2448 (2002).
- Stroke Prevention in Atrial Fibrillation investigators. The Stroke Prevention in Atrial Fibrillation (SPAF) study: final results. Circulation84, 527–539 (1991).
- Antithrombotic Triallists Collaboration. Collaborative meta-analysis of randomised trials of anti platelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br. Med. J.324, 71–86 (2002).
- Wysokinski WE, Owen WG, Fass DN, Patrzalek DD, Murphy L, McBane RD 2nd. Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi. J. Thromb. Haemost.2(9), 1637–1644 (2004).
- Morrocutti C, Amabile G, Fattaposta F et al. Indobufen versus warfarinin the secondary prevention of major vascular events in non rheumatic atrial fibrillation. [SIFA] Studio Italiano Fibrillazione Atriale Investigators. Stroke28(5), 1015–1021 (1997).
- Diener HC, Lowenthal A. Letter to the editor: reply to Dr G. Hart and Dr O. Benavente. J. Neurol. Sci.153, 112 (1997).
- Connolly SJ. The Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-W). Non-inferiority trial versus oral anticoagulation. Late Breaking Clinical Trials III. Presented at: American Heart Association Scientific Sessions. Dallas, TX, USA, 13–16 November (2005).
- Lip GYH. Thromboprophylaxis for atrial fibrillation. Lancet353, 4–6 (1999).
- Lechat P, Lardoux H, Mallet A et al. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane; FFAACS).Cerebrovasc. Dis.12, 245–552 (2001).
- Perez-Gomez F, Alegria E, Berjon J et al. L-NASPEAF investigators. Comparative effects of antiplatelet, anticoagulant or combined therapy in patients with valvular and non valvular atrial fibrillation; a randomised multicentre study. J. Am. Coll. Cardiol.44, 1557–1566 (2004).
- Perez-Gomez F, Alegria E, Berjon J et al. National Study for Prevention of Embolism in Atrial Fibrillation Investigators Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial. Eur. Heart J.27, 960–967 (2006).
- Lane D, Lip GYH. Anti-thrombotic therapy for atrial fibrillation and patients’ preferences for treatment. Age Ageing34, 1–3 (2005).
- Jones M, Mcewan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control and outcome of treatment of people with warfarin in non valvar atrial fibrillation: a record linkage study in a large British population. Heart91, 472–477 (2005).
- McCormick D, Gurwitz JH, Goldberg RJ et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long term care setting. Arch. Intern. Med.161, 2458–2463 (2001).
- Williams E, Ansari M, Lip GYH. Managing atrial fibrillation in the accident and emergency department. Q. J. Med.94, 609–614 (2001).
- Lip GYH, Zarifis J, Watson RD, Beevers DG. Physician variation in the management of patients with atrial fibrillation. Heart75, 200–205 (1996).
- Protheroe J, Fahey T, Montgomery AA, Peters TJ. The impact of patient’s preferences on the treatment of atrial fibrillation; observational study of patient based decisional analysis. Br. Med. J.320, 1380–1384 (2000).
- Fang MC, Stafford RS, Ruskin JN, Singer DE, Randall S, Daniel E. National trends in anti-arryhthmic and anti-thrombotic medication use in atrial fibrillation. Arch. Intern. Med.164, 55–60 (2004).
- Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch. Intern. Med.160, 41–46 (2000).
- Vasishta S, Toor F, Johansen A, Hasan M. Stroke prevention in atrial fibrillation: physicians’ attitudes to anticoagulation in older people. Arch. Gerontol. Geriatr.33, 219–226 (2001).
- Goudie BM, Donnan PT, Fairfield G, Al-Agilly SS, Cachia PG. Dependency rather than old age increases the risk of warfarin-related bleeding. Br. J. Gen. Pract.54, 690–692 (2004).
- Nadar S, Begum N, Kaur B, Sandhu S, Lip GYH. Patients’ understanding of anticoagulant therapy in a multiethnic population. J. R. Soc. Med.96, 175–179 (2003).
- Lip GYH, Kamath S, Jafri M, Mohammed A, Bareford D. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham atrial fibrillation project. Stroke33, 238–242 (2002).
- Hellman S, Baker L, Flores D, Lehman H, Bacon J. Effect of ethnicity on adherence to diabetic regimen. Ethnicity. Dis.7, 221–228 (1997).
- Howitt A, Armstrong D. Implementing evidence-based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. Br. Med. J.318, 1324–1327 (1999).
- Arnstein JH, Gelfand JM, Singer DE. Determinants of compliance with anticoagulation: a case control study. Am. J. Med.103(1), 11–17 (1997).
- Bruce DG, Davis WA, Cull CA, Davis TME. Diabetes education and knowledge in patients with Type 2 diabetes from the community: the freemantle study. J. Diab. Complications17, 82–89 (2003).
- Kennedy A, Nelson E, Reeves D et al. A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease. Gut53, 1639–1645 (2004).
- Wright SP, Walsh H, Ingley KM et al. Uptake of self management strategies in a heart failure management programme. Eur. J. Heart Fail.5, 371–380 (2003).
- Liu L, Yiu C, Yen D, Chou M, Lin M. Medication education for patients with epilepsy in Taiwan. Seizure12, 473–477 (2003).
- Coulter A, Entwistle V, Gilbert D. Sharing decisions with patients: is the information good enough? Br. Med. J.318, 318–322 (1999).
- Gage BF, Cardinalli AB, Owens DK, Andria B, Douglas K. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke29, 1083–1091 (1998).
- Braddock CH, Edwards KA, Hasenberg NM, Laidley TL, Levinson W. Informed decision making in outpatient practice: time to get back to basics. JAMA282, 2313–2320 (1999).
- Lane DA, Ponsford J, Shelley A, Sirpal A, Lip GYH. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The west Birmingham Atrial Fibrillation project. Int. J. Cardiol.110(3), 354–358 (2006).
- Thrall G, Lane D, Carroll D, Lip GYH. Quality of life in patients with atrial fibrillation. A systematic review. Am. J. Med.119(5)448, E1–E19 (2006).
- Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular diseases and implications for therapy. Circulation99, 2192–2217 (1999).
- Lane D, Carroll D, Ring C, Beevers DG, Lip GY. Mortality and quality of life 12 months after myocardial infarction. Effects of depression and anxiety. Psychosom. Med.63, 221–230 (2001).
- Frasure-Smith M, Lespérance F, Talajic M. Depression and 18 month prognosis after myocardial infarction. Circulation91, 999–1005 (1995).
- Langman C, Lip GYH, Lyons AC. Illness perceptions, anxiety and beliefs about medication in patients with persistent and permanent atrial fibrillation? Eur. Heart. J.553Suppl. (2001) (Abstract 22).
- Hobbs FD, Fitzmaurice DA, Mant J et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol. Assess.9(40), 1–74 (2005).
- Lip GY, Boos C. Antithrombotic therapy for atrial fibrillation. Heart92, 155–161 (2006).
- Fuster V, Ryden LE, Asinger RW et al. American College of Cardiology/American Heart Association/European Society of Cardiology Board. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary a report of the American College of Cardiology/American heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation104, 2118–2150 (2001).
- Albers GW, Diener HC, Frison L et al. SPORTIF executive steering committee for the SPORTIF V investigators. Ximelgatran vs warfarin for stroke prevention in patients with non valvular atrial fibrillation. A randomised trial. JAMA293, 690–698 (2005).
- Boos CJ, Lip GYH. Ximelagatran: an eulogy. Thrombosis Research118(3), 301–304 (2006).
- Tan KT, Makin A, Lip GYH. Factor X inhibitors. Expert Opin. Investig. Drugs12, 799–804 (2003).
- Ostermayer SH, Reisman M, Kramer PH et al. Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO System) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the International Multi-Center Feasibility Trials. J. Am. Coll. Cardiol.46, 9–14 (2005).
- Blackshear JL, Johnson WD, Odell JA et al. Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation. J. Am. Coll. Cardiol.42, 1259–1261 (2003).
- Oral H, Knight BP, Tada H et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation105, 1077–1081 (2002).
- Jais P, Weerasooriya R, Shah DC et al. Ablation therapy for atrial fibrillation: past, present and future. Cardiovasc. Res.54, 337–346 (2002).
- Karch MR, Zrenner B, Deisenhofer I et al. Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies. Circulation.111(22), 2875–2880 (2005).
- Hindricks G, Piorkowski C, Tanner H et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation112(3), 307–313 (2005).
Website
- UK National Institute of Clinical Excellence national clinical guideline on AF management www.nice.org.uk/page.aspx?o=cg36 Also published in full as follows: National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. Royal College of Physicians, London, UK (2006).